Genomic and immune landscape Of metastatic pheochromocytoma and paragangliomaBruna Calsina, Juan F. Garcı́a, Ángeles Rubio et al.|Nature Communications|2023Cited by 99
Gain-of-function mutations in DNMT3A in patients with paragangliomaLaura Remacha, Alberto Cascón, María Currás-Freixes et al.|Genetics in Medicine|2018Cited by 95
Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paragangliomaBruna Calsina, Mercedes Robledo, Luis Jaime Castro‐Vega et al.|Theranostics|2019Cited by 69
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcomeJuan María Roldán‐Romero, Cristina Rodríguez‐Antona, María Santos et al.|Modern Pathology|2020Cited by 56
Hsa‐miR‐139‐5p is a prognostic thyroid cancer marker involved in HNRNPF‐mediated alternative splicingCristina Montero‐Conde, Mercedes Robledo, Osvaldo Graña‐Castro et al.|International Journal of Cancer|2019Cited by 40